133 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Owens DGC. A Guide to the Extrapyramidal Side-­Effects of Antipsychotic Drugs, 2nd edn. Cambridge: Cambridge University Press; 2014.
2. Martino D, et al. Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-­analysis. Can J Psychiatry 2018; 63:706743718777392.
3. Barnes TRE. The Barnes akathisia scale – revisited. J Psychopharm 2003; 17:365–370.
4. Jouini L, et al. Akathisia among patients undergoing antipsychotic therapy: prevalence, associated factors, and psychiatric impact. Clin Neuropharmacol 2022; 45:89–94.
5. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-­treatments meta-­analysis. Lancet 2014; 382:951–962.
6. Misdrahi D, et al. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the national FACE-­SZ cohort. J Clin Psychiatry 2019; 80:18m12246.
7. Ali T, et al. Antipsychotic-­induced extrapyramidal side effects: a systematic review and meta-­analysis of observational studies. PLoS One 2021; 16:e0257129.
8. Siafis S, et al. Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-­effects: a systematic review and dose-­response meta-­analysis. Mol Psychiatry 2023; 28:3267–3277.
9. Kim JH, et al. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clin Neuropharmacol 2003; 26:312–316.
10. Potvin S, et al. Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. J Neurol Neurosurg Psychiatry 2006; 77:796–798.
11. Potvin S, et al. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-­analysis. Schizophr Res 2009; 113:181–188.
12. Hansen LK, et al. Movement disorders in patients with schizophrenia and a history of substance abuse. Hum Psychopharmacol 2013; 28:192–197.
13. Duke PJ, et al. South Westminster schizophrenia survey. Alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset. Br J Psychiatry 1994; 164:630–636.
14. Zivkovic M, et al. The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol. J Clin Psychopharmacol 2013; 33:593–599.
15. Nedic Erjavec G, et al. SLC6A3, HTR2C and HTR6 gene polymorphisms and the risk of haloperidol-­induced parkinsonism. Biomedicines 2022; 10:3237.
16. Kibitov AA, et al. The ANKK1/DRD2 gene TaqIA polymorphism (rs1800497) is associated with the severity of extrapyramidal side effects of haloperidol treatment in CYP2D6 extensive metabolizers with schizophrenia spectrum disorders. Drug Metab Pers Ther 2023; 38:133–142.
17. Cortese L, et al. Relationship of neuromotor disturbances to psychosis symptoms in first-­episode neuroleptic-­naive schizophrenia patients. Schizophr Res 2005; 75:65–75.
18. Puri BK, et al. Spontaneous dyskinesia in first episode schizophrenia. J Neurol Neurosurg Psychiatry 1999; 66:76–78.
19. Rybakowski JK, et  al. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. Eur Neuropsychopharmacol 2014; 24:1500–1505.
20. Cuesta MJ, et al. Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-­naive patients with first-­episode psychosis: a 6-­month follow-­up study. Schizophr Bull 2014; 40:1164–­1173.
21. Cuesta MJ, et al. Motor abnormalities in first-­episode psychosis patients and long-­term psychosocial functioning. Schizophr Res 2018; 200:97–103.
22. Pappa S, et al. Spontaneous movement disorders in antipsychotic-­naive patients with first-­episode psychoses: a systematic review. Psychol Med 2009; 39:1065–1076.
23. Barnes TR, et al. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985; 42:874–878.
24. Gervin M, et al. Assessment of drug-­related movement disorders in schizophrenia. Adv Psychiatr Treat 2000; 6:332–341.
25. Pringsheim T, et al. The assessment and treatment of antipsychotic-­induced akathisia. Can J Psychiatry 2018; 63:719–729.
26. Seemuller F, et al. Akathisia and suicidal ideation in first-­episode schizophrenia. J Clin Psychopharmacol 2012; 32:694–698.
27. Leong GB, et al. Neuroleptic-­induced akathisia and violence: a review. J Forensic Sci 2003; 48:187–189.
28. Owens DC. Tardive dyskinesia update: the syndrome. BJPsych Advances 2018; 25:57–69.
29. Martino D, et al. Scales for antipsychotic-­associated movement disorders: systematic review, critique, and recommendations. Mov Disord 2023; 38:1008–1026.
30. Simpson GM, et al. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212:11–19.
31. Barnes TRE. A rating scale for drug-­induced akathisia. BJPsychiatry 1989; 154:672–676.
32. Guy W. Abnormal Involuntary Movement Scale (II7-­AIMS). In: ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare; 1976:534–537.
33. McEvoy JP. How to assess tardive dyskinesia symptom improvement with measurement-­based care. J Clin Psychiatry 2020; 81:NU19047BR19044C.
34. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154 Suppl 4:1–63.
35. van Harten PN, et al. Acute dystonia induced by drug treatment. BMJ 1999; 319:623–626.
36. Bollini P, et  al. Antipsychotic drugs: is more worse? A meta-­analysis of the published randomized control trials. Psychol Med 1994; 24:307–316.

130 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 37. Halstead SM, et al. Akathisia: prevalence and associated dysphoria in an in-­patient population with chronic schizophrenia. Br J Psychiatry 1994; 164:177–183. 38. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003; 29:547–558. 39. Juncal-­Ruiz M, et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non-­affective psychosis: a 6-­week randomised study of antipsychotic treatment. Psychopharmacology (Berl) 2017; 234:2563–2570. 40. Caligiuri M. Tardive dyskinesia: a task force report of the American Psychiatric Association. Hosp Community Psychiatry 1993; 44:190. 41. Patterson-­Lomba O, et al. Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis. BMC Neurol 2019; 19:174. 42. Widschwendter CG, et al. Antipsychotic-­induced tardive dyskinesia: update on epidemiology and management. Curr Opin Psychiatry 2019; 32:179–184. 43. Carbon M, et al. Tardive dyskinesia risk with first-­ and second-­generation antipsychotics in comparative randomized controlled trials: a meta-­analysis. World Psychiatry 2018; 17:330–340. 44. Caroff SN, et al. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry 2011; 72:295–303. 45. Yasui-­Furukori N, et al. The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study. Neuropsychiatr Dis Treat 2014; 10:1209–1212. 46. Miller CH, et al. Managing antipsychotic-­induced acute and chronic akathisia. Drug Saf 2000; 22:73–81. 47. Havaki-­Kontaxaki BJ, et al. Treatment of severe neuroleptic-­induced tardive torticollis. Ann Gen Hosp Psychiatry 2003; 2:9. 48. Hennings JM, et al. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:1167–1171. 49. Poyurovsky M, et al. Efficacy of low-­dose mirtazapine in neuroleptic-­induced akathisia: a double-­blind randomized placebo-­controlled pilot study. J Clin Psychopharmacol 2003; 23:305–308. 50. Salem H, et  al. Revisiting antipsychotic-­induced akathisia: current issues and prospective challenges. Curr Neuropharmacol 2017; 15:789–798. 51. Stryjer R, et  al. Treatment of neuroleptic-­induced akathisia with the 5-­HT2A antagonist trazodone. Clin Neuropharmacol 2003; 26:137–141. 52. Stryjer R, et al. Trazodone for the treatment of neuroleptic-­induced acute akathisia: a placebo-­controlled, double-­blind, crossover study. Clin Neuropharmacol 2010; 33:219–222. 53. Stryjer R, et al. Mianserin for the rapid improvement of chronic akathisia in a schizophrenia patient. Eur Psychiatry 2004; 19:237–238. 54. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004; 26:265–270. 55. Rathbone J, et al. Anticholinergics for neuroleptic-­induced acute akathisia. Cochrane Database Syst Rev 2006; (3):CD003727. 56. Vanegas-­Arroyave N, et  al. An evidence-­based update on anticholinergic use for drug-­induced movement disorders. CNS Drugs 2024; 38:239–254. 57. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61 Suppl 4:21–26. 58. Kinon BJ, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28:985-­996. 59. Bai YM, et al. Risperidone for severe tardive dyskinesia: a 12-­week randomized, double-­blind, placebo-­controlled study. J Clin Psychiatry 2003; 64:1342–1348. 60. Tenback DE, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-­month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005; 66:1130–1133. 61. Woods SW, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010; 71:463–474. 62. Pena MS, et al. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2011; 26:147–152. 63. Stegmayer K, et al. Tardive dyskinesia associated with atypical antipsychotics: prevalence, mechanisms and management strategies. CNS Drugs 2018; 32:135–147. 64. Simpson GM. The treatment of tardive dyskinesia and tardive dystonia. J Clin Psychiatry 2000; 61 Suppl 4:39–44. 65. Peritogiannis V, et al. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature. J Psychopharmacol 2010; 24:1121–1125. 66. Kishi T, et  al. Valbenazine for tardive dyskinesia: a systematic review and network meta-­analysis. Int Clin Psychopharmacol 2023; 38:369–374. 67. Solmi M, et al. Treatment of tardive dyskinesia with VMAT-­2 inhibitors: a systematic review and meta-­analysis of randomized controlled trials. Drug Des Devel Ther 2018; 12:1215–1238. 68. Hauser RA, et al. Long-­term deutetrabenazine treatment for tardive dyskinesia is associated with sustained benefits and safety: a 3-­year, open-­label extension study. Front Neurol 2022; 13:773999. 69. Frank S, et al. Clinical utility of deutetrabenazine as a treatment option for chorea associated with Huntington’s disease and tardive dyskinesia. Ther Clin Risk Manag 2023; 19:1019–1024. 70. Golsorkhi M, et al. Comparative analysis of deutetrabenazine and valbenazine as VMAT2 inhibitors for tardive dyskinesia: a systematic review. Tremor Other Hyperkinet Mov 2024; 14:13. 71. Zhang WF, et al. Extract of ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-­blind, placebo-­controlled trial. J Clin Psychiatry 2010; 72:615–621. 72. Bergman H, et al. Systematic review of interventions for treating or preventing antipsychotic-­induced tardive dyskinesia. Health Technol Assess 2017; 21:1–218. 73. Ricciardi L, et al. Treatment recommendations for tardive dyskinesia. Can J Psychiatry 2019; 64:388–­399. 74. Bhidayasiri R, et al. Evidence-­based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81:463–469.